PODCAST: Announcing Crowell & Moring’s Regulatory Forecast 2017 and Trump: The First Year Series — C&M's Trump: The First Year Series
Client Alert | 1 min read | 05.11.17
On May 9, Crowell & Moring launched its third annual Regulatory Forecast. The 2017 edition, subtitled “What Trump Means for Business,” provides in-depth analysis on how the new administration, Congress, and the federal courts are changing the regulatory landscape and what it means for business in the months ahead. With this publication, we are also announcing the launch of our new Trump: The First Year series about the regulatory changes emerging from the White House under the new administration. In this first episode of the series, Regulatory Forecast co-editors Dan Wolff and Richard Lehfeldt sit down to discuss the Forecast and what to expect from the series.
In this 12 minute podcast, Richard and Dan discuss what you will find in our Regulatory Forecast 2017 and what lessons businesses should take from the publication. The forecast is available at crowell.com/regulatoryforecast.
Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
